Stocks
Amgen Stock Surges Past High Amid Record Q2 Sales
Amgen Inc. (US0311621009) is trading near its 52-week high after second-quarter revenue reached $10.05 billion and adjusted EPS came in at $6.29.
The company's latest earnings release on August 4, 2026 lifted full-year guidance, with management leaning on growth from products such as Repatha, Evenity, and Uplizna.
Quarterly numbers show a 9.5% increase in revenue from $9.17 billion a year earlier, while adjusted EPS increased to $6.29 from $6.02.
The company now expects 2026 revenue of $38.2 billion to $39.4 billion and adjusted EPS of $22.30 to $23.50, surpassing prior revenue expectations of $37.0 billion to $38.4 billion.